Candida glabrata candidemia

@article{Chakrabarti2015CandidaGC,
  title={Candida glabrata candidemia},
  author={Arunaloke Chakrabarti},
  journal={Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine},
  year={2015},
  volume={19},
  pages={138 - 139}
}
  • Arunaloke Chakrabarti
  • Published 1 March 2015
  • Biology, Medicine
  • Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine
In this issue, the article “Candida glabrata candidemia: An emerging threat in critically ill patients” demands discussion on this topic as C. glabrata candidemia is difficult to manage and the patients have high mortality. Clinicians, epidemiologists, microbiologists, and basic scientists across the world are working on the epidemiology, pathogenesis, virulence factors, genetics, and drug resistance of C. glabrata to understand the natural course of the disease caused by the fungus and to… 
Comments on “Candida glabrata candidemia; an emerging threat in critically ill patients”
  • Armin Ahmed, A. Azim, A. Baronia
  • Medicine, Biology
    Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
  • 2015
Sir, The article “Candida glabrata candidemia; An emerging threat in critically ill patients” very well highlights the importance of this emerging species.[1] Due to delay in time to positivity
Antifungal Resistance in Clinical Isolates of Candida glabrata in Ibero-America
TLDR
The limited information on this subject in the region of Ibero-America emphasizes the need to identify the pathogens at the species level and perform antifungal susceptibility tests that may lead to the appropriate use of these drugs and the optimal doses in order to avoid the development of antIFungal resistance or multi-resistance.
Drug susceptibility of fungi isolated from ICU patients
TLDR
F fungi from the genus Candida are the etiological factors for ICU infections; 3/5 of them are caused by C. albicans, mostly of the code 2 576 174, characteristic for strains isolated from hospitalized patients; it is necessary to determine the species of the fungus and its susceptibility to drugs, which allows to conduct effective therapy.
Multilocus Sequence Typing and Antifungal Susceptibility of Vaginal and Non-vaginal Candida glabrata Isolates From China
TLDR
The authors' survey revealed cross-resistance in vaginal and non-vaginal C. glabrata isolates, and the most common genotype was ST7 (81 strains), followed by ST10 (14 strains) and ST15 (11 strains).
Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibility
TLDR
Local epidemiology of candidaemia at the authors' centre was distinct regarding prevalence and change of spectrum of species, with the emergence of multidrug-resistant C. auris and resistance in other species, routine AFST has become imperative.

References

SHOWING 1-9 OF 9 REFERENCES
Candida glabrata: a review of its features and resistance
TLDR
This review intends to present an excerpt of the biology, epidemiology, and pathology of C. glabrata, and detail an approach to its resistance mechanisms based on studies carried out up to the present.
Two unlike cousins: Candida albicans and C. glabrata infection strategies
TLDR
This review compares and contrast the strategies of C. albicans and C. glabrata to attach to and invade into the host, obtain nutrients and evade the host immune response, and explains why both fungi are successful as commensals and as pathogens of humans.
Candida glabrata candidemia: An emerging threat in critically ill patients
  • Ashish Gupta, Anuragini Gupta, A. Varma
  • Medicine, Biology
    Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
  • 2015
TLDR
Candida glabrata was the 3rd most common Candida causing candidemia in ICUs with a incidence of 0.21/1000 ICU admissions and patients who were treated with fluconazole showed better outcome than patients treated with amphotericin B.
Echinocandin resistance: an emerging clinical problem?
TLDR
Echinocandin resistance is increasingly encountered and its occurrence makes susceptibility testing essential, particularly in patients with prior exposure, and the further development of rapid and user-friendly commercially available susceptibility platforms is warranted.
Echinocandins for Primary Therapy of Candidemia: Time for a Paradigm Shift?
TLDR
Echinocandins have demonstrated favorable clinical responses with a low incidence of adverse effects in patients with candidemia due to both Candida albicans and non-albicans Candida species and, as such, have emerged as the preferred initial therapy.
Global trends in the distribution of Candida species causing candidemia.
  • J. Guinea
  • Medicine, Biology
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2014
TLDR
Only five species account for 92% of cases of candidemia, but considerable differences are found between the number of cases caused by C. glabrata and C. parapsilosis, and the distribution varies in population-based studies conducted in different geographical areas.
Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure
TLDR
A paradigm that considers prior echinocandin exposure and caspofungin MICs accurately classified treatment outcomes for C. glabrata invasive candidiasis is accurately classified.
Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata
TLDR
These data document the broad emergence of coresistance over time to both azoles and echinocandins in clinical isolates of C. glabrata and suggest that the first-line treatment of bloodstream infections due to Candida glabRata is still the best option.
Incidence, characteristics and outcome of ICU-acquired candidemia in India
TLDR
A high burden of candidemia in Indian ICUs, early onset after ICU admission, higher risk despite less severe physiology score at admission and a vast spectrum of agents causing the disease with predominance of C. tropicalis is highlighted.